
5 Things to Look for at the European Society of Cardiology 2019 Congress
Studies on anticoagulants and SGLT2 inhibitors, and guidelines for dyslipidemia and more are anticipated at the meeting.
For most of us in the United States, next weekend signals Labor Day and the unofficial end of summer. But for those in the world of cardiology, it will bring the 2019 Congress of the European Society of Cardiology (ESC), an increasingly important meeting that this year travels to Paris from August 31 to September 4.
What's happening at ESC that we should be following between our barbecues and our final trips to the pool? Plenty, it turns out. Here are 5 things to look for at the ESC 2019 Congress:
1. Full results for DAPA-HF.
This is a last-minute addition to the late-breaker session to be held Sunday afternoon, September 1. We already know from the top-line results announced
2. Details for THEMIS.
This is another study where AstraZeneca
3. Real-world evidence for apixaban.
Data from the NAXOS study for the novel oral anticoagulant apixaban (Eliquis) will be presented in a Sunday morning late-breaking session. The study uses a nationwide health insurance database in France to study 8 cohorts of patients with nonvalvular atrial fibrillation, including those who have taken anti-coagulants before and those who have not. This is the first and largest real-world data study of its kind or oral anticoagulants in Europe.
4. Guidelines galore.
The ESC adheres to a published
5. Novel approaches to prevention.
Studies on preventing disease and early death will be presented throughout the Congress, including
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.